Test Price
2,800 AED✅ Home Collection Available
NME8 Gene Primary Ciliary Dyskinesia Type 6 Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✔ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited processing, detecting single nucleotide variants and copy number changes across the NME8 gene.
- ✔ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM for standard whole blood specimens.
- ✔ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed Consultant Medical Geneticist.
- ✔ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The NME8 Gene Primary Ciliary Dyskinesia Type 6 Genetic Test identifies pathogenic variants in the NME8 gene responsible for primary ciliary dyskinesia (PCD), a rare autosomal recessive disorder that impairs mucociliary clearance. Affected individuals experience chronic respiratory infections, sinusitis, otitis media, and male infertility due to defective sperm flagella. Definitive molecular diagnosis enables tailored airway clearance therapies, regular pulmonary monitoring, and informed family planning. Our laboratory employs Next-Generation Sequencing (NGS) with comprehensive CNV analysis to ensure full gene coverage including deep intronic regions, reducing the need for reflex testing.
| Feature | Our NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) with CNV Analysis – full gene coverage | Sanger sequencing – limited to point mutations, misses large deletions/duplications |
| Sensitivity | >99.9% for single nucleotide variants & indels; >95% for CNVs | ~95% for point mutations only; no CNV detection |
| Turnaround Time | 3–4 Weeks | 6–8 Weeks |
| Specimen | Whole blood or DNA FTA card (home collection available) | Whole blood only, lab visit required |
| Price (AED) | 2,800 | ~2,500 |
Physician Insight & Safety Protocols
“A molecular confirmation of Primary Ciliary Dyskinesia type 6 through NME8 sequencing provides families with a definitive diagnosis after years of recurrent infections and diagnostic uncertainty. This genetic result must always be interpreted alongside ciliary motility studies, nasal nitric oxide measurement, and high-resolution chest imaging. The information is invaluable for reproductive counseling and early intervention planning. Patients should maintain all current respiratory therapies unless explicitly advised otherwise by their managing physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication & Clinical Advisory
Important Precautions Before Testing
Do not discontinue or alter any prescribed medication, including antibiotics, bronchodilators, or airway clearance therapies, without direct consultation with your physician. Genetic testing is a diagnostic adjunct and does not replace ongoing clinical management. If you are on anticoagulant therapy, inform your phlebotomist prior to the blood draw so that appropriate precautions can be arranged.
Patient Exclusion & Red Flag Criteria
Safety Screening for Specimen Collection
- Exclusion: Active febrile illness (temperature >38.5°C), severe anemia (hemoglobin <8 g/dL), or current anticoagulant therapy that cannot be safely paused under medical supervision.
- Deferral: Recent blood transfusion or stem cell transplant within 4 weeks may compromise DNA purity and necessitate rescheduling.
- Emergency Red Flags: Acute worsening of cough, cyanosis, or severe shortness of breath requires immediate evaluation at the nearest UAE emergency department. Do not delay urgent care while awaiting genetic results.
Patient FAQ & Clinical Guidance
1. What does a positive NME8 genetic test mean for my child’s long-term health?
A positive result confirms the presence of two pathogenic variants in the NME8 gene, establishing the molecular diagnosis of Primary Ciliary Dyskinesia type 6. This allows your physician to implement targeted airway clearance protocols, schedule regular pulmonary function monitoring, and initiate early interventions to reduce the risk of bronchiectasis and respiratory decline.
2. Why is NGS recommended instead of traditional sequencing for this gene?
Next-Generation Sequencing simultaneously analyzes the entire NME8 gene including deep intronic regions, splice sites, and copy number variations that Sanger sequencing cannot detect. This comprehensive approach eliminates the need for repeat testing and provides a complete molecular picture in a single workflow.
3. How are results delivered and what support is provided after testing?
Results are typically available within 3 to 4 weeks and are delivered via a secure, encrypted patient portal. Every report includes a telephonic post-test counselling session with a DHA-licensed genetic specialist to explain findings, discuss implications for family members, and coordinate further care with your referring physician.
4. Can home collection be arranged for this genetic test?
Yes. For standard whole blood specimens, our VIP Mobile Phlebotomy service provides temperature-controlled cold-chain home collection daily from 8 AM to 11 PM. A trained phlebotomist visits your residence, collects the sample under sterile conditions, and transports it directly to our ISO-accredited laboratory in Dubai Healthcare City.
UAE Regulatory & Data Privacy Adherence
Compliance Framework & Patient Rights
All genetic testing performed at DNA Labs UAE is conducted under the regulatory oversight of the Dubai Health Authority (DHA Facility License No. 1143). We operate in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure health information exchange. Clinical safety and informed consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data is encrypted, access-controlled, and never shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | NME8 Gene Primary Ciliary Dyskinesia Type 6 Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood or DNA FTA Card (VIP Mobile Phlebotomy Home Collection Available) |
| Methodology Used | Next-Generation Sequencing (NGS) with CNV Analysis |
| ICD-10-CM Code | J98.4 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians